111 related articles for article (PubMed ID: 27329084)
1. (11)C-methylaminoisobutyric acid (MeAIB) PET for evaluation of prostate cancer: compared with (18)F-fluorodeoxyglucose PET.
Arimoto MK; Higashi T; Nishii R; Kagawa S; Takahashi M; Kishibe Y; Yamauchi H; Ishitoya S; Oonishi H; Nakamoto Y; Togashi K
Ann Nucl Med; 2016 Oct; 30(8):553-62. PubMed ID: 27329084
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic usefulness of an amino acid tracer, α-[N-methyl-(11)C]-methylaminoisobutyric acid ( (11)C-MeAIB), in the PET diagnosis of chest malignancies.
Nishii R; Higashi T; Kagawa S; Kishibe Y; Takahashi M; Yamauchi H; Motoyama H; Kawakami K; Nakaoku T; Nohara J; Okamura M; Watanabe T; Nakatani K; Nagamachi S; Tamura S; Kawai K; Kobayashi M
Ann Nucl Med; 2013 Nov; 27(9):808-21. PubMed ID: 23824782
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT.
Shiiba M; Ishihara K; Kimura G; Kuwako T; Yoshihara H; Sato H; Kondo Y; Tsuchiya S; Kumita S
Ann Nucl Med; 2012 Feb; 26(2):138-45. PubMed ID: 22069194
[TBL] [Abstract][Full Text] [Related]
4. Differential Diagnosis between Low-Grade and High-Grade Astrocytoma Using System A Amino Acid Transport PET Imaging with C-11-MeAIB: A Comparison Study with C-11-Methionine PET Imaging.
Nishii R; Higashi T; Kagawa S; Arimoto M; Kishibe Y; Takahashi M; Yamada S; Saiki M; Arakawa Y; Yamauchi H; Okuyama C; Hojo M; Munemitsu T; Sawada M; Kobayashi M; Kawai K; Nagamachi S; Hirai T; Miyamoto S
Contrast Media Mol Imaging; 2018; 2018():1292746. PubMed ID: 30026674
[TBL] [Abstract][Full Text] [Related]
5. Estimation of Tumor Volumes by 11C-MeAIB and 18F-FDG PET in an Orthotopic Glioblastoma Rat Model.
Halle B; Thisgaard H; Hvidsten S; Dam JH; Aaberg-Jessen C; Thykjær AS; Høilund-Carlsen PF; Schulz MK; Andersen C; Kristensen BW
J Nucl Med; 2015 Oct; 56(10):1562-8. PubMed ID: 26229144
[TBL] [Abstract][Full Text] [Related]
6. Increased Prostate Cancer Glucose Metabolism Detected by
Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of integrated PET/MRI for detection and localization of prostate cancer: Comparative study of multiparametric MRI and PET/CT.
Lee MS; Cho JY; Kim SY; Cheon GJ; Moon MH; Oh S; Lee J; Lee S; Woo S; Kim SH
J Magn Reson Imaging; 2017 Feb; 45(2):597-609. PubMed ID: 27586519
[TBL] [Abstract][Full Text] [Related]
8. Diffusion-weighted MRI,
Kitajima K; Yamamoto S; Kawanaka Y; Nakanishi Y; Yamada Y; Go S; Kanematsu A; Kaida H; Yamakado K
Hell J Nucl Med; 2020; 23(1):34-39. PubMed ID: 32222730
[TBL] [Abstract][Full Text] [Related]
9. Uptake of [N-methyl-11C]alpha-methylaminoisobutyric acid in untreated head and neck cancer studied by PET.
Sutinen E; Jyrkkiö S; Alanen K; Någren K; Minn H
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):72-7. PubMed ID: 12483412
[TBL] [Abstract][Full Text] [Related]
10. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
11. Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?
Reesink DJ; Fransen van de Putte EE; Vegt E; De Jong J; van Werkhoven E; Mertens LS; Bex A; van der Poel HG; van Rhijn BW; Horenblas S; Meijer RP
J Urol; 2016 Apr; 195(4 Pt 1):907-12. PubMed ID: 26598424
[TBL] [Abstract][Full Text] [Related]
12. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
[TBL] [Abstract][Full Text] [Related]
13. ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.
Rowe SP; Gage KL; Faraj SF; Macura KJ; Cornish TC; Gonzalez-Roibon N; Guner G; Munari E; Partin AW; Pavlovich CP; Han M; Carter HB; Bivalacqua TJ; Blackford A; Holt D; Dannals RF; Netto GJ; Lodge MA; Mease RC; Pomper MG; Cho SY
J Nucl Med; 2015 Jul; 56(7):1003-1010. PubMed ID: 26069305
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy.
Beauregard JM; Blouin AC; Fradet V; Caron A; Fradet Y; Lemay C; Lacombe L; Dujardin T; Tiguert R; Rimac G; Bouchard F; Pouliot F
Cancer Imaging; 2015 Mar; 15(1):2. PubMed ID: 25889163
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution of [11C] methylaminoisobutyric acid, a tracer for PET studies on system A amino acid transport in vivo.
Sutinen E; Jyrkkiö S; Grönroos T; Haaparanta M; Lehikoinen P; Någren K
Eur J Nucl Med; 2001 Jul; 28(7):847-54. PubMed ID: 11504081
[TBL] [Abstract][Full Text] [Related]
16. Preoperative detection of prostate cancer: a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging.
Watanabe H; Kanematsu M; Kondo H; Kako N; Yamamoto N; Yamada T; Goshima S; Hoshi H; Bae KT
J Magn Reson Imaging; 2010 May; 31(5):1151-6. PubMed ID: 20432351
[TBL] [Abstract][Full Text] [Related]
17. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
[TBL] [Abstract][Full Text] [Related]
18. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
19. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
